WENDY JANE KOOPMAN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family GRAND RAPIDS, MI NPI 1891728069
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family MI Janssen Biotech, Inc. All categories
General Payments — all program years on this page
$2,594.31
- Category: General Payments
- Program years: PY2022–2024
- Record count: 104
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,488.41 across 55 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,243.42 | 52 |
| Education | $244.99 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $193.97 | 6 |
| Genentech USA, Inc. | $108.75 | 5 |
| Ipsen Biopharmaceuticals, Inc | $107.90 | 2 |
| Acerta Pharma LLC | $101.21 | 2 |
| SEAGEN INC. | $96.00 | 1 |
| Incyte Corporation | $88.47 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $86.10 | 4 |
| Karyopharm Therapeutics Inc. | $66.95 | 3 |
| Merck Sharp & Dohme Corporation | $63.81 | 2 |
| Stemline Therapeutics Inc. | $60.55 | 2 |
| Gilead Sciences, Inc. | $51.35 | 3 |
| Lilly USA, LLC | $46.96 | 2 |
| GlaxoSmithKline, LLC. | $39.01 | 2 |
| Inari Medical, Inc. | $33.26 | 1 |
| Regeneron Healthcare Solutions, Inc. | $30.97 | 1 |
| Rigel Pharmaceuticals, Inc. | $30.90 | 2 |
| E.R. Squibb & Sons, L.L.C. | $30.47 | 2 |
| PharmaEssentia USA Corporation | $28.73 | 1 |
| Myriad Genetic Laboratories, Inc. | $27.68 | 1 |
| Agios Pharmaceuticals, Inc. | $24.17 | 1 |
| EISAI INC. | $23.12 | 1 |
| JAZZ PHARMACEUTICALS INC. | $23.01 | 1 |
| Coherus Biosciences Inc. | $22.64 | 1 |
| Kyowa Kirin, Inc. | $19.51 | 1 |
| PFIZER INC. | $18.64 | 1 |
| Deciphera Pharmaceuticals Inc. | $17.77 | 1 |
| Alnylam Pharmaceuticals Inc. | $17.06 | 1 |
| ABBVIE INC. | $16.31 | 1 |
| Blueprint Medicines Corporation | $13.14 | 1 |
By program year
Records — PY2024 (55)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.